SGLT-2 inhibitors are the first class of drugs to target renal glucose reabsorption as a means of reducing hyperglycemia in type 2 diabetes mellitus. Emerging data strongly suggest that this novel drug class will, in the very near future, have a role to play in diabetes management. Thus, it is important that health care providers who treat patients with diabetes are aware of the most recent data on these agents and the implications for clinical practice.

Developed by a faculty of renowned, international diabetes experts led by Julio Rosenstock, MD, this 2-part educational activity will provide clinicians with an interpretation of recent clinical data, and explore the potential role of SGLT-2 inhibitors in diabetes care.

This continuing medical education activity is jointly sponsored by Albert Einstein College of Medicine of Yeshiva University and Haymarket Medical Education and supported by an educational grant from Bristol-Myers Squibb.

Please note: this program is also offered in a number of other languages. Click the appropriate link below to get started:

A Review of the Current Data

1.0 / AMA PRA Category 1 Credit(s)™ 

The first component of this 2-part educational activity, the clinical monograph will provide endocrinologists, cardiologists, and general practitioners who manage the care of patients with type 2 diabetes with the latest data on the SGLT-2 inhibitors. A detailed explanation of the unique mechanisms of action and the safety and tolerability profiles of this drug class will be provided, and the results of key clinical trials will be discussed.


Translating Data to Practice

1.0 / AMA PRA Category 1 Credit(s)™

Four international diabetes experts will further elucidate the future role of the SGLT-2 inhibitors in the T2DM treatment arsenal. Safety issues, tailoring therapy to the needs of each patient, and identifying and addressing potential clinical barriers will be explored.



is free, fast, and customized just for you!

Already a member?

Sign In Now »